Results from a new study investigating the benefits of Sativex in neuropathic pain in people with multiple sclerosis (MS) have shown it gave long-term pain relief.
The study followed 42 people with MS who took Sativex - a cannabis-based drug trialled by GW Pharmaceuticals. This randomized withdrawal study evaluated 42 people with central neuropathic pain who had previously been in a Sativex MS neuropathic pain study and who continued to take Sativex on an open label basis for 12 weeks. They were then randomized to Sativex or placebo for a further 4 weeks in a double-blinded manner. The purpose of this 4-week study was to assess the maintenance of pain control in patients who remain on Sativex versus those who switch to placebo.
Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog. ============================================